SSG
OMED

Summit Securities Group’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Summit Securities Group’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-10
Closed -$1K – 855
2014
Q3 		$1K Buy
+10
New +$201 ﹤0.01% 674

Other funds holding OMED

ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Apex Capital Orinda, California $938M AUM 4.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Summit Securities Group's OMED Position: Q2 2015 in Review

Summit Securities Group sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2015, closing a stake of 116 shares — an estimated $3K sold.

Summit Securities Group first reported a position in OMED in Q1 2015 and held it in 1 quarter. The position peaked at $3K in Q1 2015. 83 funds tracked by Wall St. Rank hold OMED as of Q2 2015.

  • Summit Securities Group reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • Summit Securities Group sold 116 OncoMed Pharmaceuticals, Inc. shares in Q2 2015, an estimated $3K.
  • Summit Securities Group first reported a position in OncoMed Pharmaceuticals, Inc. in Q1 2015 and held it in 1 quarter.
  • Summit Securities Group's OncoMed Pharmaceuticals, Inc. position peaked at $3K in Q1 2015.
  • 83 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2015.

Based on Summit Securities Group's 13F filing for Q2 2015, filed 5 Aug 2015.